No Carolina / NY / Florida
Ph: 561.316.3330

Avenda Health Receives FDA Investigational Device Exemption for AI-enabled Prostate Cancer Therapy

Summation

  • With no new FDA approvals for the treatment of localized prostate cancer in more than four decades, we look forward to working alongside our clinical sites to collect the data necessary to bring iQuest and FocalPoint to market and into the patient care environment,” said Brittany Berry-Pusey, co-founder and COO of Avenda Health.
  • iQuest uses artificial intelligence and deep learning to map a patient’s prostate cancer, providing physicians with a precise location of the cancer within the gland and a better understanding of the extent of the disease to aid in treatment planning.
  • The IDE will allow these two technologies to be used together in a randomized control trial to show superiority over standard of care for the treatment of prostate cancer.

Avenda Health, an AI healthcare company creating the future of prostate cancer care, today announced its FocalPoint ablation system powered by iQuest, a patient management AI software, has received investigational device exemption (IDE) from the US Food and Drug Administration (FDA).

The IDE will allow these two technologies to be used together in a randomized control trial to show superiority over standard of care for the treatment of prostate cancer.

iQuest uses artificial intelligence and deep learning to map a patient’s prostate cancer, providing physicians with a precise location of the cancer within the gland and a better understanding of the extent of the disease to aid in treatment planning. In a retrospective study of 50 patients presented at the 2022 American Urological Association annual meeting, iQuest improved tumor margin creation1 over conventional treatment planning from 56 percent to 80 percent2.

“Our mission is to advance prostate cancer therapy so patients no longer need to choose between treatment or quality of life,” said Dr. Shyam Natarajan, co-founder and CEO of Avenda Health. “Using the latest deep learning technology, iQuest gives physicians and their patients more insights to identify the best treatment on an individual basis. We’re thrilled to receive IDE approval so we can further prostate cancer research for the millions of men affected each year.”

FocalPoint is Avenda Health’s focal laser ablation system designed to treat localized prostate cancer in-office while preserving quality of life. Prostate cancer is the most common internal cancer in men, but 50 percent+ of patients treated with existing therapies lose their sexual or urinary function or both, severely impacting quality of life. In 2021, the FDA granted Avenda Health with Breakthrough Device Designation, indicating there is a high likelihood the Avenda Health technology will be better than the standard of care.

“This clinical trial will play a key role in advancing our breakthrough technology to improve prostate cancer care. With no new FDA approvals for the treatment of localized prostate cancer in more than four decades, we look forward to working alongside our clinical sites to collect the data necessary to bring iQuest and FocalPoint to market and into the patient care environment,” said Brittany Berry-Pusey, co-founder and COO of Avenda Health.

Derived from experts at UCLA, Avenda Health was founded with support from a National Cancer Institute grant, which was the catalyst to fund the company’s participation in many clinical trials at various prototype stages. The FocalPoint system re-imagines laser ablation, which has been used to treat thousands of patients, enabling prostate cancer treatment outside an MRI under ultrasound guidance in a doctor’s office. In each of its technologies, Avenda Health is building a more personalized and targeted standard of care for prostate cancer.

Other FDA News of Interest

Indica Labs Receives FDA Clearance for HALO AP Dx Digital Pathology Platform for Use with Hamamatsu Images Acquired with the NanoZoomer® S360MD Slide Scanner

Indica Labs, an industry leader in AI-powered digital pathology solutions, and Hamamatsu Photonics K.K., a pioneer in whole slide imaging systems, announce that the...

FDA Grants AI-Powered Notal Vision Home OCT “SCANLY” De Novo Marketing Authorization

“We are very excited to receive FDA authorization to market SCANLY Home OCT as the first-ever patient self-operated, home-use device that gives physicians remote access to high-resolution, cross-sectional retinal images and AI-based analytical biomarkers of their patients eyes between office visits,” said Kester Nahen, PhD, CEO of Notal Vision. “We look forward to supporting our referring physicians in navigating their wet AMD patients’ care.”

Atraverse Medical Receives FDA Clearance for HOTWIRE™ Left Heart Access Device, Oversubscribes Seed Round with $12.5M Invested

The HOTWIRE system, invented by Atraverse Medical Co-Founders Dr. Steven Mickelsen and Eric Sauter, introduces a paradigm shift in left-heart access.

By using this website you agree to accept Medical Device News Magazine Privacy Policy